China's first and only approved third generation BCR-ABL inhibitor olverembatinib included into the 2022 National Reimbursement Drug List

Ascentage Pharma

18 January 2023 - Ascentage Pharma and Innovent Biologics today announced that the novel drug olverembatinib has been included into the China 2022 National Reimbursement Drug List for the treatment of T315I mutant chronic-phase chronic myeloid leukaemia and accelerated phase CML. 

The new version of the National Reimbursement Drug List will take effect on 1 March 2023.

Read Ascentage Pharma press release

Michael Wonder

Posted by:

Michael Wonder